CN103463118A

CN103463118A - Application of geniposide in preparation of parkinsonism disease treatment medicines

Info

Publication number: CN103463118A
Application number: CN2013103474734A
Authority: CN
Inventors: 李琳; 陈毅美; 张彦芳; 刘越泽; 高充; 刘珂; 赵娟
Original assignee: Shanxi Medical University
Current assignee: Shanxi Medical University
Priority date: 2013-08-12
Filing date: 2013-08-12
Publication date: 2013-12-25

Abstract

The invention relates to a use of geniposide, and concretely relates to a new use of geniposide in the preparation of parkinsonism disease (PD) treatment medicines. The application fills a gap in researches of the protection effect of geniposide to PD nerves, and provides a new traditional Chinese medicinal treatment method for the PD treatment. A PD model group, a geniposide treatment group and a contrast group are adopted to carry out experiments in the invention, and experiment results show that the geniposide can effectively alleviate the mouse motor and coordination ability damages caused by MPTP, and can obviously protect the reduction of the expression level of tyrosine hydroxylase in the brain, so the geniposide can be used as a clinic medicine for the PD treatment.

Description

The application of geniposide in the Parkinsonian medicine of preparation treatment

Technical field

The present invention relates to the purposes of geniposide, be specially the new purposes of geniposide aspect the treatment parkinson disease.

Background technology

Geniposide (Geniposide) is a kind of Fructus Gardeniae extract, has the effect of heat-clearing and toxic substances removing, and the iridoid glucoside is soluble in water, is the main pharmacodynamics composition of Fructus Gardeniae.Geniposide all has significant curative effect to diseases such as digestive system, cardiovascular systeies.In addition, geniposide also has the effect of certain antiinflammatory and treatment soft tissue injury.

the genipin molecular structural formula

Simultaneously, diabetes and multiple neurodegenerative diseases be as alzheimer disease (Alzheimer ' s disease, AD), and parkinson disease (Parkinson ' s disease, PD) have very close contact.The epidemiological analysis demonstration, the probability that the insulin-resistant states patient suffers from PD can significantly increase (Aviles-Olmos et al., Brain. 2013 Feb; 136 (Pt 2): 374-84. doi:10.1093/brain/aws009. Epub 2012 Feb 17).This makes and utilizes Remedies for diabetes treatment PD to become possibility.

Summary of the invention

The present invention has filled up the blank of geniposide to the research of PD neuroprotective effect, for the treatment of PD provides a kind of new treatment by Chinese herbs method.

The application of geniposide in the Parkinsonian medicine of preparation treatment.

Applicant's research is thought, as a kind of g protein coupled receptor (GPCR), after GLP-1 is activated, can activate multiple downstream signal approach, such as the activation of PKA, and activation of PI3K signal path etc.Thereby play and correct cellular metabolism extremely and the effect of Promote cell's growth by the activation of these signal transduction pathways.Simultaneously, because very important effect has been played in these signal pathway imbalances in the pathogenesis of PD.The applicant further thinks, geniposide can be used as a kind of GLP-1 receptor stimulating agent, utilizes the neuroprotective of geniposide, can play the therapeutical effect to PD.

The applicant adopts 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and each continuous 7 days (1 times/day) lumbar injection C57BL mouses of 30mg/kg are made the PD animal model.Matched group adopts the same concentrations normal saline.Treatment group adopts 100mg/kg geniposide lumbar injection C57BL mouse (injection MPTP was injected after hour).After 7 days, PD model group and treatment group are all no longer carried out the MPTP injection, and the PD model group changes normal saline into and continues injection 7 days, and treatment group changes geniposide into and continues successive administration 7 days, as shown in Figure 1.Simultaneously, the rat motor ability is observed in the swimming behavior scoring.

After this, utilize the balanced capacity of Rotarod behavioristics measuring animal.

Finally, utilize the Westernblot method to measure the tyrosine hydroxylase expression.

The accompanying drawing explanation

Fig. 1 is the flow chart of mice swimming behavior experiment.

Fig. 2 is the comparison diagram of mice swimming behavior experimental result.

Fig. 3 is the comparison diagram of mice Rotarod roller experimental result.

Fig. 4 is that Western blot measures tyrosine hydroxylase (tyrosine hydroxylase, TH) level.

Fig. 5 is the comparison diagram of geniposide to tyrosine hydroxylase (TH) level affects.

The specific embodiment

1, concrete experiment material and content

1.1, laboratory animal

Experiment material is chosen C57BL mouse (body weight 24 ± 1g), and C57BL mouse is provided by Mountain Western Medicine S University's animal center.Raising condition: 25 ± 2 ℃ of temperature, humidity (40 ± 10) %.Natural lighting, ad lib, water inlet.

1.2, the test medication

Geniposide is buied by the calm and peaceful pharmaceutical companies in Chengdu.Geniposide lumbar injection concentration is 5mg/ml, a 0.3ml.

1.3, swimming behavior experiment

The experiment of C57BL swimming behavior is carried out in the lucite water vat of 20cm * 30cm * 20cm.Mice is positioned in water and observes its strokes, and make an appraisal.Standards of grading are: in 1 minute, swim and be recorded as 30 minutes continuously; Most of the time swimming is floating once in a while is recorded as 25 minutes; Flotation time accounts for the whole tested time and remembers 20 minutes more than 50%; The swimmer remembers 15 minutes once in a while; Swim with hind leg once in a while and float on water tank one side person and be designated as 10 minutes.

1.4, Rotarod behavioristics experiment

Mice is positioned on the Rotarod roller bearing of diameter 6cm, rotating speed 20r/min, adapt to and start experiment for 5 times later.Record the stop incubation period (for the first time drop time) of mice on roller bearing.

1.5, Westernblot measures the tyrosine hydroxylase expression

Mice behavior research is directly breaked end later, gets brain, according to stereotaxic atlas, gets the black substance part.The potent protein lysate in the green skies carries out protein cleavage and adds PMSF, carries out protein cleavage.Subsequently by turn/min of lysate 12000,4 ℃ of centrifugal 20min.Get supernatant, the Bradford method is measured and is extracted protein concentration.Utilize each histone concentration of loading buffer trim.SDS-PAGE carries out protein electrophorese, applied sample amount 6 ~ 10 μ l.After electrophoresis, transferring film (pvdf membrane).The sealing of 0.3%TBST gelatin solution.Primary antibodie is hatched (the anti-Mus tyrosine hydroxylase of rabbit antibody: Abcam:1:500; The anti-Mus β of rabbit-Actin antibody: Abcam:1:1000), 4 ℃ are spent the night.TBST washes film three times, two anti-goat anti-rabbit igg-H& L(Abcam:1:5000) incubated at room 40min.Exposure, analyze band.The expression ratio that between each group, statistical representation is destination protein and internal reference albumen β-Actin.

2, experimental result:

2.1, mice in giving 5～10min of MPTP, limb tremor has appearred, instability of gait, perpendicular tail, the variation of the behavioristicss such as the back of a bow.The basic recovery normally after 20h.And, along with the geniposide administration number of times increases, its acute symptom alleviates gradually.

The swimming behavior result:

As shown in Figure 2, swimming behavior is learned experimental result (n=10).The scoring of MPTP group mice swimming behavior is significantly lower than matched group (*: p<0.01).Individually dosed group of swimming behavior scoring of geniposide (Geniposide) and matched group are without significant difference.With MPTP group mice, compare, geniposide+MPTP group mice swimming behavior scoring significantly improves (#:p<0.01).Proved that geniposide can alleviate the mouse movement dysfunction that MPTP brings out.

2.2, Rotarod roller experiment

As shown in Figure 3, the Rotarod roller is tested, and mainly measures the balanced capacity (n=10) of mice.The incubation period (seconds) for dropping for the first time on the inherent roller of mice 2min that this figure shows.The independent injection group of geniposide (Geniposide) and Control group there is no obvious difference, and the MPTP mice drops and is starkly lower than Control (*: p<0.01) incubation period, proves that MPTP has formed the injury effect to the balanced capacity of mice.Contrast MPTP group, treatment group (MPTP+Geniposide) significantly improves (#:p<0.01) incubation period, proves that geniposide alleviated the infringement of the mice balanced capacity that MPTP induces significantly.

2.3, Western blot measures tyrosine hydroxylase (tyrosine hydroxylase, TH) level, as shown in Figure 4.

As shown in Figure 5, the impact (n=6) of geniposide on tyrosine hydroxylase (TH) level.With the Control group, compare, significant difference does not appear in individually dosed group of TH level of geniposide (Geniposide).MPTP processes and has obviously reduced mice TH expression (*: p<0.01).Treatment group (MPTP+Geniposide) is compared with the MPTP group, and the TH level significantly increases (#:p<0.01).

In sum, the experimental result demonstration, geniposide can effectively be alleviated the mouse movement ability that MPTP causes, and the damage of the coordination ability also has significant protective effect to the reduction of tyrosine hydroxylase expression in brain simultaneously.Therefore, the applicant thinks that geniposide can be used as the clinical treatment medicine of a kind of PD.

Claims

1. the application of geniposide in the Parkinsonian medicine of preparation treatment.